Factor VIII, human plasma-derived: Pediatric drug

information

Copyright 1978-2023 Lexicomp, Inc. All rights reserved.

Contributor Disclosures

(For additional information see "Factor VIII, human plasma-derived: Drug information" and see "Factor
VIII, human plasma-derived: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp ( show table)

Brand Names: US
Hemofil M; Koate; Koate-DVI

Therapeutic Category
Antihemophilic Agent; Blood Product Derivative

Dosing: Pediatric

Hemophilia A

Hemophilia A: Individualize dosage based on clinical response and factor VIII

activity evaluated at baseline and at regular intervals during treatment. In
general, administration of factor VIII 1 unit/kg will increase circulating factor VIII
levels by ~2% of normal. Patients with inhibitory antibodies to factor VIII may
require higher doses, more frequent administration, and/or selection of
alternative therapy.

General dosing for control and prevention of bleeding episodes or

perioperative management: Note: Dosage is expressed in units of factor
VIII activity and must be individualized based on formulation, severity of
factor VIII deficiency, extent and location of bleed, individualized incremental
recovery using factor VIII activity assays, and clinical situation of patient.
Infants, Children, and Adolescents (ages vary by product; see product-
specific labeling for approved ages): IV:

Formula for units required to raise blood level:

Number of Factor VIII Units required = body weight (in kg) x 0.5
units/kg per units/dL x desired factor VIII level increase (units/dL
or %)

For example, for a desired 100% level in a 25 kg patient who has

an actual level of 20%: Number of Factor VIII Units needed = 25 kg
x 0.5 units/kg per units/dL x 80% = 1,000 units

Treatment recommendations (WFH [Srivastava 2013]): Note: Factor

VIII level may either be expressed as % or as units/dL.

Intermittent IV: Infants, Children and Adolescents: The following

recommendations reflect guideline recommendations for general
dosing requirements; may vary from those found within
prescribing information or practitioner preference. Frequency is
based on type of bleed or surgery and varies by product; see
specific product labeling for details. Dosing frequency most
commonly corresponds to the half-life of factor VIII but should be
determined based on an assessment of factor VIII levels (if
available) before the next dose.

Site of Hemorrhage/Clinical Desired Factor

FrequencyA Duration
Situation VIII Peak Level

Every 8 to 24 1 to 2 days, may be longer

Joint 40% to 60%
hours if response is inadequate

2 to 3 days, sometimes
Superficial muscle/no Every 8 to 24
40% to 60% longer if response is
neurovascular compromise hours
inadequate

Iliopsoas and deep muscle Initial: 80% to Every 8 to 24

Initial: 1 to 2 days
with neurovascular injury, or 100% hours
AFrequency is based on type of bleed or surgery and varies by product; see specific product
labeling for details.
Site of Hemorrhage/Clinical Desired Factor
FrequencyA Duration
Situation VIII Peak Level
substantial blood loss Maintenance: 3 to 5 days,
Maintenance: sometimes longer as
30% to 60% secondary prophylaxis
during physiotherapy

Initial: 80% to
Initial: 1 to 7 days
100% Every 8 to 24
CNS/Head
Maintenance: hours
Maintenance: 8 to 21 days
50%

Initial: 80% to
Initial: 1 to 7 days
100% Every 8 to 24
Throat and neck
Maintenance: hours
Maintenance: 8 to 14 days
50%

Initial: 80% to
Initial: 7 to 14 days
100% Every 8 to 24
Gastrointestinal
Maintenance: hours Maintenance: Not
50% specified

Every 8 to 24
Renal 50% 3 to 5 days
hours

Every 8 to 24
Deep laceration 50% 5 to 7 days
hours

Preop: 80% to
Single dose
100%

Postop: 60% to
Postop: 1 to 3 days
80%
Surgery (major)
Postop: 40% to Every 8 to 24
Postop: 4 to 6 days
60% hours

Postop: 30% to
Postop: 7 to 14 days
50%

Preop: 50% to
Single dose
80%
Surgery (minor) Postop: 1 to 5 days
Postop: 30% to Every 8 to 24
depending on procedure
80% hours
type
AFrequency is based on type of bleed or surgery and varies by product; see specific product
labeling for details.
 Continuous IV infusion: Infants, Children, and Adolescents: Note:
In general, administration of factor VIII 4 units/kg/hour will
increase circulating factor VIII levels by 1 unit/mL (Prelog 2016).

Control and prevention of bleeding episodes: Limited data

available: Note: For patients who require prolonged periods of
treatment (eg, intracranial hemorrhage or surgery) to avoid
peaks and troughs associated with intermittent infusions
(Batorova 2002; Poon 2012; Prelog 2016; WFH [Srivastava
2013]):

Following initial bolus to achieve the desired factor VIII

level: Initial dosing: 2 to 4 units/kg/hour; adjust dose based
on frequent factor VIII assays and calculation of factor VIII
clearance at steady-state using the following equations:

Factor VIII clearance (mL/kg/hour) = (current infusion rate in

units/kg/hour) / (plasma factor VIII level in units/mL)

New infusion rate (units/kg/hour) = (factor VIII clearance in

mL/kg/hour) x (desired plasma factor VIII level in units/mL)

Perioperative management: Limited data available: Initial: 25 to

50 units/kg prior to surgery, followed by continuous infusion at
a rate of 3 to 5 units/kg/hour; regimen based on 2 studies
evaluating use in pediatric surgery patients (age range: 0.9 to
17 years); rate was adjusted and additional boluses given as
needed to maintain desired factor VIII level (Batorova 2012;
Dingli 2002).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Adult
(For additional information see "Factor VIII, human plasma-derived: Drug
information")

Hemophilia A, without inhibitors

Hemophilia A, without inhibitors:

Treatment and control of bleeding episodes or perioperative

management:

Intermittent IV bolus dosing: IV: Utilize steps 1 to 3 to determine

intermittent bolus dosing strategy. Individualize dosage based on
coagulation studies performed prior to treatment and at regular intervals
during treatment. In general, administration of factor VIII 1 unit/kg will
increase circulating factor VIII levels by ~2 units/dL (WFH [Srivastava
2020]).

Step 1: Determine desired factor VIII peak level and anticipated

duration of therapy based on the World Federation of Hemophilia
(WFH) treatment recommendations; see table. Selection of the lower-
dose practice pattern requires closer observation with the potential
for requiring escalation to higher doses based on clinical response.

Note: For patients without inhibitors and receiving emicizumab

who experience breakthrough bleeding, antihemophilic factor
should be dosed to target the desired peak factor VIII levels
outlined in the table as emicizumab is not indicated for treatment
of bleeding episodes.

Antihemophilic Factor (Human) WFH Treatment Recommendationsd

 Lower-dose practice pattern Higher-dose practice pattern

Desired peak Treatment Desired peak Treatment

Type of hemorrhage or factor VIII duration factor VIII duration
surgery level (units/dL) (days) level (units/dL) (days)

Joint 10 to 20 1 to 2a,c 40 to 60 1 to 2a,c

Superficial muscle/no
neurovascular
10 to 20 2 to 3a 40 to 60 2 to 3a
compromise (except
iliopsoas)

Iliopsoas or deep muscle with neurovascular injury or substantial blood loss:

Initial 20 to 40 1 to 2 80 to 100 1 to 2

Maintenance 10 to 20 3 to 5b 30 to 60 3 to 5b

Intracranial:

Initial 50 to 80 1 to 3 80 to 100 1 to 7

30 to 50 4 to 7 50 8 to 21
Maintenance
20 to 40 8 to 14 - -

Throat and Neck:

Initial 30 to 50 1 to 3 80 to 100 1 to 7

Maintenance 10 to 20 4 to 7 50 8 to 14

Gastrointestinal:

Initial 30 to 50 1 to 3 80 to 100 7 to 14

Maintenance 10 to 20 4 to 7 50 -

Renal 20 to 40 3 to 5 50 3 to 5

Deep laceration 20 to 40 5 to 7 50 5 to 7

Surgery (major):

Preop 60 to 80 - 80 to 100 -

30 to 40 1 to 3 60 to 80 1 to 3

Postop 20 to 30 4 to 6 40 to 60 4 to 6

10 to 20 7 to 14 30 to 50 7 to 14
aMay be longer if response is inadequate.
bSometimes longer as secondary prophylaxis during physical therapy.
cA single dose may be sufficient for some joint bleeds; determine need for additional doses
based on clinical response.
dWFH [Srivastava 2020].
 Lower-dose practice pattern Higher-dose practice pattern

Desired peak Treatment Desired peak Treatment

Type of hemorrhage or factor VIII duration factor VIII duration
surgery level (units/dL) (days) level (units/dL) (days)

Surgery (minor):

Preop 40 to 80 - 50 to 80 -

Postop 20 to 50 1 to 5 30 to 80 1 to 5
aMay be longer if response is inadequate.
bSometimes longer as secondary prophylaxis during physical therapy.
cA single dose may be sufficient for some joint bleeds; determine need for additional doses
based on clinical response.
dWFH [Srivastava 2020].

Step 2: Calculate dose using desired peak factor VIII level from step 1
and the following equation:

Factor VIII units required = [(desired peak factor VIII level −

patient’s baseline factor VIII level) × body weight (kg)]/2

Note: Factor VIII level units are units/dL.

Example for 50 kg patient with desired peak factor VIII level of 35

units/dL and baseline factor VIII level of 5 units/dL:

Factor VIII units required = [(35 units/dL − 5 units/dL) × 50 kg]/2 =

750 units of factor VIII

Step 3: Determine need for repeat dosing based on manufacturer’s

recommended frequency of repeat dosing. Note: Frequency of
administration must also take into consideration subsequent factor
VIII activity measurements and the clinical response.

Antihemophilic Factor (Human) Administration Frequency According to Clinical Scenario

Bleeding event Surgery

Minor Moderate Major Minor bleeding Major

Product severity severity severity risk bleeding risk
 Bleeding event Surgery

Minor Moderate Major Minor bleeding Major

Product severity severity severity risk bleeding risk

Hemofil- Every 12 to Every 12 to 24 Every 8 to 24 Single dose Every 8 to 24

M 24 hours hours hours typically adequate hours

Every 12 Every 12 Every 12 Every 12

Koate Every 12 hours
hours hours hours hours

Continuous infusion dosing (Batorova 2002; Batorova 2012; Holme

2018; Martinowitz 1992; Poon 2012; Rickard 1995; WFH [Srivastava 2020]
):

Note: Continuous infusion administration is preferred over

intermittent bolus administration for patients requiring prolonged
treatment courses (eg, postoperative management after surgery with
major bleeding risk). To ensure safe and effective use, only products
with extended stability information should be used. Extended stability
information may not be available for all products; contact product
manufacturer to obtain current recommendations. Use of a smart
infusion pump with small volume infusion capability is also necessary.

IV: Administer an initial bolus to achieve the desired factor VIII level
(see steps 1 and 2 under intermittent bolus dosing), then initiate
continuous infusion at 2 to 4 units/kg/hour. Adjust dose based on
frequent factor assays (at least daily) and calculation of factor VIII
clearance at steady-state using the below equations.

Factor VIII clearance (mL/kg/hour) = (current infusion rate in

units/kg/hour) divided by (measured factor VIII level in units/mL)

New infusion rate (units/kg/hour) = (factor VIII clearance in

mL/kg/hour) x (desired factor VIII level in units/mL)

Note: With infusion dose increases, re-bolus should be considered

to achieve target factor VIII level more quickly. See steps 1 and 2
under intermittent bolus dosing to determine re-bolus dose.
 Routine prophylaxis to prevent or reduce the frequency of bleeding
episodes in patients with moderate/severe hemophilia A, without
inhibitors: IV: 25 to 40 units/kg of factor VIII concentrate every 2 to 3 days.
Preferably, dosing should be tailored to ensure trough factor VIII levels of at
least 1% and ideally ≥3% to 5% are achieved, but prophylaxis targets should
be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose
escalation should be considered for patients adherent to prescribed
prophylaxis but still experiencing breakthrough bleeding events (WFH
[Srivastava 2020]).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Adverse Reactions
The following adverse drug reactions and incidences are derived from product
labeling unless otherwise specified.

1% to 10%:

Gastrointestinal: Abdominal pain (5%), nausea (5%)

Hematologic & oncologic: Increased factor VIII inhibitors (6%)

Local: Inflammation at injection site (2%)

Nervous system: Headache (≤5%), nervousness (10%), paresthesia (5%)

Ophthalmic: Blurred vision (5%)

<1%:

Cardiovascular: Chest tightness

Gastrointestinal: Dysgeusia
 Nervous system: Dizziness

Miscellaneous: Fever

Postmarketing:

Cardiovascular: Bradycardia, chest pain, edema, flushing, hypotension,

tachycardia

Dermatologic: Hyperhidrosis, pruritus, skin rash, urticaria

Gastrointestinal: Diarrhea, vomiting

Hematologic & oncologic: Hemolytic anemia

Hypersensitivity: Facial edema, hypersensitivity reaction (including

anaphylaxis)

Nervous system: Chills, fatigue, irritability, tonic-clonic seizure

Neuromuscular & skeletal: Musculoskeletal pain

Ophthalmic: Ocular hyperemia, visual impairment

Respiratory: Bronchospasm, cough, cyanosis, dyspnea, hyperventilation

Contraindications
Hypersensitivity (eg, anaphylaxis) to antihemophilic factor (human) or any component
of the formulation; hypersensitivity to mouse proteins (Hemofil M only).

Warnings/Precautions
Concerns related to adverse effects:

• Antibody formation: The development of factor VIII antibodies has been

reported with antihemophilic factors; monitor for signs of formation of
antibodies to factor VIII. Suspect factor VIII antibodies if the plasma factor VIII
level does not increase as expected or if bleeding is not controlled after
administration.
 • Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis)
may occur; discontinue immediately if hypersensitivity symptoms occur and
administer appropriate treatment.

Special populations:

• Blood types A, B, and AB: Contains trace amounts of blood groups A and B
isohemagglutinins; use caution when large or frequently repeated doses are
given to individuals with blood groups A, B, and AB. Monitor patients for signs
of intravascular hemolysis and falling hematocrit; discontinue therapy and
consider administration of serologically compatible type O red blood cells if
progressive hemolytic anemia occurs.

Dosage form specific issues:

• Albumin: Products vary by preparation method; final formulations contain

human albumin.

• Human plasma: Product of human plasma; may potentially contain infectious

agents which could transmit disease. Screening of donors, as well as testing
and/or inactivation or removal of certain viruses, reduces the risk. Infections
thought to be transmitted by this product should be reported to the
manufacturer. Hepatitis A and B vaccination is recommended for all patients
receiving plasma derivatives.

• Mouse protein: Hemofil M contains trace amounts of mouse protein; use is

contraindicated in patients with hypersensitivity to mouse protein.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known
as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been
reported following exposure to pharmaceutical products containing
polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley
1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and
hepatic failure have been reported in premature neonates after receiving
parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See
manufacturer's labeling.
 • von Willebrand factor: Some products may contain naturally occurring von
Willebrand factor for stabilization; however, efficacy has not been established
for the treatment of von Willebrand disease.

Other warnings/precautions:

• Appropriate use: Dosage requirements will vary in patients with factor VIII
inhibitors; optimal treatment should be determined by clinical response.
Frequency of use is determined by the severity of the disorder or bleeding
pattern.

Warnings: Additional Pediatric Considerations

Formation of factor VIII inhibitors (neutralizing antibodies to AHF human) may occur;
reported incidence is 3% to 52%; an increase of inhibitor antibody concentration is
seen at 2 to 7 days, with peak concentrations at 1 to 3 weeks after therapy; children
<5 years of age are at greatest risk; higher doses of AHF may be needed if antibody is
present; if antibody concentration is >10 Bethesda units/mL, patients may not
respond to larger doses and alternative treatment modalities may be needed;
monitor patients appropriately. Allergic-type hypersensitivity reactions, including
anaphylaxis, may occur; discontinue therapy immediately if urticaria, hives,
hypotension, tightness of the chest, wheezing, dyspnea, faintness, or anaphylaxis
develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen)
may be needed.

Dosage Forms Considerations

Strengths expressed with approximate values. Consult individual vial labels for exact
potency within each vial.

Dosage Forms: US
Excipient information presented when available (limited, particularly for generics);
consult specific product labeling.

Solution Reconstituted, Intravenous:

 Koate: ~250 units (1 ea); ~500 units (1 ea); ~1000 units (1 ea) [contains albumin
human, polyethylene glycol (macrogol), polysorbate 80]

Solution Reconstituted, Intravenous [preservative free]:

Hemofil M: ~250 units (1 ea); ~500 units (1 ea); ~1000 units (1 ea); ~1700 units
(1 ea) [contains albumin human, polyethylene glycol (macrogol)]

Koate-DVI: ~500 units (1 ea); ~1000 units (1 ea) [contains albumin human,
polyethylene glycol (macrogol), polysorbate 80]

Generic Equivalent Available: US

No

Pricing: US
Solution (reconstituted) (Hemofil M Intravenous)

250 unit (Price provided is per AHF Unit): $1.86

500 unit (Price provided is per AHF Unit): $1.86

1000 unit (Price provided is per AHF Unit): $1.86

1700 unit (Price provided is per AHF Unit): $1.86

Solution (reconstituted) (Koate Intravenous)

250 unit (Price provided is per AHF Unit): $1.73

500 unit (Price provided is per AHF Unit): $1.73

1000 unit (Price provided is per AHF Unit): $1.73

Solution (reconstituted) (Koate-DVI Intravenous)

500 unit (Price provided is per AHF Unit): $1.58

1000 unit (per each): $1.58

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is

provided as reference price only. A range is provided when more than one
manufacturer's AWP price is available and uses the low and high price reported by the
manufacturers to determine the range. The pricing data should be used for
benchmarking purposes only, and as such should not be used alone to set or
adjudicate any prices for reimbursement or purchasing functions or considered to be
an exact price for a single product and/or manufacturer. Medi-Span expressly
disclaims all warranties of any kind or nature, whether express or implied, and
assumes no liability with respect to accuracy of price or price range data published in
its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or
consequential damages arising from use of price or price range data. Pricing data is
updated monthly.

Additional Information
One unit of AHF is equal to the factor VIII activity present in 1 mL of normal human
plasma. If bleeding is not controlled with adequate dose, test for the presence of
factor VIII inhibitor; larger doses of AHF may be therapeutic with inhibitor titers <10
Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor
titers >10 Bethesda units/mL (due to the very large AHF doses required); other
treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates,
recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in
patients with inhibitor titers >10 Bethesda units/mL.

Administration: Pediatric
Parenteral: IV administration only; use administration sets/tubing provided by
manufacturer (if provided). Administer through a separate line, do not mix with drugs
or other IV fluids.

Intermittent IV: Rate of administration should be determined by patient

tolerability (maximum rates vary by product).

Hemofil M, Koate: 10 mL/minute.

Monoclate-P: 2 mL/minute.

WFH recommendations (Srivastava 2013): Infuse at a rate determined by age:

Young children: 100 units/minute; Adults: 3 mL/minute.
 Continuous IV infusion: Further dilution after initial reconstitution is unnecessary
(Batorova 2012; Prelog 2016).

Administration: Adult
IV: Administer at a rate comfortable to the patient (≤10 mL/minute).

Continuous infusion (off-label rate): Has also been administered as a continuous

infusion to avoid peaks and troughs associated with intermittent infusions in
patients who require prolonged treatment periods. Use a smart infusion pump
with small volume infusion capability. Refer to protocols for product selection and
preparation details (Batorova 2002; Batorova 2012; Holme 2018; Martinowitz 1992;
Poon 2012; Rickard 1995; WFH [Srivastava 2020]).

Storage/Stability
Store under refrigeration, 2°C to 8°C (36°F to 46°F); do not freeze. Use within 3
hours of reconstitution. Do not refrigerate after reconstitution, precipitation may
occur.

Hemofil M: May also be stored at room temperature not to exceed 30°C (86°F).

Koate: May also be stored at 25°C (77°F) for ≤6 months. Store in original
package to protect from light.

Use
Control and prevention of bleeding episodes in patients with hemophilia A
(classical hemophilia) and perioperative management of patients with hemophilia
A (All indications: Monoclate-P, Hemofil M: FDA-approved in pediatric patients [age
not specified] and adults; Koate: FDA approved in ages ≥2.5 years and adults). Has
also been used to provide therapeutic effects in patients with acquired factor VIII
inhibitors <10 Bethesda units/mL.

Note: Antihemophilic Factor (Human) is not indicated for the treatment of von
Willebrand disease.

Medication Safety Issues

Sound-alike/look-alike issues:

Factor VIII may be confused with Factor XIII

Other safety concerns:

Confusion may occur due to the omitting of “Factor VIII” from some product
labeling. Review product contents carefully prior to dispensing any
antihemophilic factor.

Metabolism/Transport Effects
None known.

Drug Interactions
(For additional information: Launch drug interactions program)
There are no known significant interactions.

Pregnancy Considerations
Pregnant carriers of hemophilia A may have an increased bleeding risk following
invasive procedures, spontaneous miscarriage, termination of pregnancy, and
delivery; close surveillance is recommended. Factor VIII levels should be monitored at
the first antenatal visit, once or twice during the third trimester, prior to surgical or
invasive procedures, and at delivery. Although factor VIII concentrations increase in
pregnant patients, factor VIII replacement is recommended if concentrations are <50
units/dL and any of the following occur: need for invasive procedures (including
delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or
active bleeding. Hemostatic factor VIII concentrations should be maintained for at
least 3 to 5 days following invasive procedures or postpartum. If a replacement
product is indicated, a recombinant product is preferred (NHF 2017; RCOG [Pavord
2017]; WFH [Srivastava 2020]).

Monitoring Parameters
Monitor factor VIII levels prior to and during treatment; heart rate and blood pressure
(before and during IV administration); monitor for signs and symptoms of bleeding,
hemoglobin and hematocrit, and for hypersensitivity reactions; monitor for
development of inhibitor antibodies by clinical observation (eg, inadequate control of
bleeding with adequate doses) and laboratory tests (eg, inhibitor level, Bethesda
assay). In patients with blood groups A, B, or AB who receive large or frequent doses,
monitor Hct, direct Coombs' test, and signs of intravascular hemolysis.

Reference Range
Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII (WFH
[Srivastava 2013])

Severe: Factor level <1% of normal.

Moderate: Factor level 1% to 5% of normal.

Mild: Factor level 5% to <40% of normal.

Mechanism of Action
Protein (factor VIII) in normal plasma which is necessary for clot formation and
maintenance of hemostasis; activates factor X in conjunction with activated factor IX;
activated factor X converts prothrombin to thrombin, which converts fibrinogen to
fibrin, and with factor XIII forms a stable clot

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Does not readily cross the placenta

Half-life elimination: Mean: 14.8 to 17.5 hours

Brand Names: International

Find brand name(s) by country (for United States and Canada see separate Brand
Names sections)

Enter a Country or Country Code

International Brand Names by Country

For country code abbreviations ( show table)

(AE) United Arab Emirates: Factor viii | Koate dvi; (AR) Argentina: Beriate p | Emoclot |
Fanhdi | Hemofil m | Koate dvi | Octanate | Optivate; (AT) Austria: Beriate p |
Haemoctin sdh | Octanate; (BE) Belgium: Factane | Monoclate P; (BG) Bulgaria: Beriate
| Emoclot DI | Hemofil m | Koate | Octanate; (BR) Brazil: Beriate p | Fanhdi | Hemofil
| Koate dvi; (CH) Switzerland: Beriate | Haemoctin | Octanate; (CL) Chile: Koate dvi |
Octanate; (CN) China: Hemoraas | Kang si ping; (CO) Colombia: Beriate | Emoclot |
Factane | Fanhdi | Haemoctin sdh | Hemofil m | Koate | Koate dvi | Koate HP | Koate
mr dvi | Octanate | Optivate; (CZ) Czech Republic: Beriate | Beriate p | Criostat |
Fanhdi | Haemoctin sdh | Octanate; (DE) Germany: Beriate | Beriate p | Fanhdi |
Haemoctin sdh | Hemofil m | Monoclate P | Octanate | Optivate | Profilate; (EC)
Ecuador: Emoclot | Fanhdi | Octanate; (EE) Estonia: Beriate | Hemofil m | Octanate |
Octonativ-M; (EG) Egypt: Koate dvi | Octanate; (ES) Spain: Beriate p | Fanhdi |
Haemoctin | Hemofil m | Octanate; (FI) Finland: Amofil | Octafil | Octafil low; (FR)
France: Factane | Hemofil m | Monoclate | Octanate LV; (GB) United Kingdom: Beriate
p | Fanhdi | Haemoctin | Hemofil m | Monoclate P | Octanate | Optivate | Profilate;
(GR) Greece: Fanhdi | Haemoctin | Octanate; (HK) Hong Kong: Haemoctin sdh | Koate
| Koate dvi; (HU) Hungary: Beriate | Beriate hs | Beriate p | Fanhdi | Haemoctin sdh |
Hemofil m | Koate dvi | Octanate | Octonativ-M; (ID) Indonesia: Aafact | Beriate |
Haemoctin | Koate dvi | Koate HP | Koate HT | Octanate; (IN) India: Beriate | Hemorel
a; (IT) Italy: Beriate p | Emoclot d.i. | Fanhdi | Haemoctin | Hemofil m | Koate |
Octanate; (JP) Japan: Koate | Profilate; (KR) Korea, Republic of: Monoclate P; (KW)
Kuwait: Beriate; (LB) Lebanon: Beriate; (LT) Lithuania: Haemoctin sdh | Hemofil m |
Koate HP | Octanate; (LU) Luxembourg: Octanate; (LV) Latvia: Cilveka koagulacijas
faktora VIII | Haemoctin sdh | Hemofil m | Kaote dvi | Koate dvi | Octanate; (MX)
Mexico: Beriate | Beriate p | Fanhdi | Haemoctin sdh | Hemofil m | Koate dvi |
Monoclate P | Octanate | Optivate | Plasmaclot; (MY) Malaysia: Beriate | Factor viii |
Hemofil m | Octanate | Optivate; (NL) Netherlands: Aafact | Octanate; (NO) Norway:
Octanate; (PE) Peru: Factor viii | Octanate | Optivate; (PH) Philippines: Hemofil m |
Koate | Octanate; (PL) Poland: Beriate | Emoclot | Fanhdi | Octanate; (PR) Puerto Rico:
Hemofil m | Koate dvi | Koate HP; (PT) Portugal: Beriate p | Emoclot | Factor viii |
Fanhdi | Hemofil m | Monoclate P | Octanate; (PY) Paraguay: Factor viii green cross |
Koate dvi; (RO) Romania: Fanhdi | Haemoctin sdh | Octanate | Optivate; (RU) Russian
Federation: Agemfil a | Beriate | Emoclot | Emoclot d.i. | Fanhdi | Haemoctin |
Hemofil m | Koate dvi | Octanate; (SA) Saudi Arabia: Factor viii | Koate dvi | Octanate
| Optivate; (SE) Sweden: Ahf-Koncentrat | Beriate | Beriate p | Hemofil m | Koate |
Monoclate P | Octanate | Octonativ-M | Profilate; (SG) Singapore: Octanate; (SI)
 Slovenia: Octanate; (SK) Slovakia: Fanhdi; (TH) Thailand: Fanhdi | Haemoctin sdh |
Hemofil m | Profilate; (TN) Tunisia: Beriate | Emoclot DI | Haemoctin sdh | Octanate;
(TR) Turkey: AHF M | Beriate p | Emoclot | Factane | Factor viii | Fanhdi | Haemoctin
sdh | Hemofil m | Koate dvi | Koate HP | Nordiate | Octanate; (TW) Taiwan: Beriate p
| Factor viii | Haemoctin sdh | Koate dvi | Koate HP | Monoclate P; (UA) Ukraine:
Beriate | Emoclot | Koate dvi | Octanate; (UY) Uruguay: Emoclot | Haemoctin sdh |
Hemofil m | Koate dvi | Koate HP; (VE) Venezuela, Bolivarian Republic of: Factor viii

REFERENCES

1. Abildgaard CF, Simone JV, Corrigan JJ, et al. Treatment of Hemophilia With Glycine-
Precipitated Factor VIII. N Engl J Med. 1966;275(9):471-475. [PubMed 5917942]
2. Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics.
1986;77(4):593-597. [PubMed 3960626]
3. Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment
Standardisation Board. Continuous infusion in haemophilia: current practice in
Europe. Haemophilia. 2012;18(5):753-759. [PubMed 22530687]
4. Batorova A, Martinowitz U. Continuous infusion of coagulation factors.
Haemophilia. 2002;8(3):170-177. [PubMed 12010406]
5. Berntorp E. Impact of Replacement Therapy on the Evolution of HIV Infection in
Hemophiliacs. Thromb Haemost. 1994;71(6):678-683. [PubMed 7974331]
6. Centers for Disease Control (CDC). Unusual syndrome with fatalities among
premature infants: association with a new intravenous vitamin E product. MMWR
Morb Mortal Wkly Rep. 1984;33(14):198-199.
http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm [PubMed 6423951]
7. Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL. Continuous factor VIII
infusion therapy in patients with haemophilia A undergoing surgical procedures
with plasma-derived or recombinant factor VIII concentrates. Haemophilia.
2002;8(5):629-634. [PubMed 12199670]
8. Hemofil M (antihemophilic factor [human]) [prescribing information]. Lexington,
MA: Takeda Pharmaceuticals USA Inc; March 2023.
 9. Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor
concentrates during intensive treatment. Haemophilia. 2018;24(1):24-32.
doi:10.1111/hae.13331 [PubMed 28873263]
10. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension.
Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
11. Koate (Antihemophilic Factor [Human]) [prescribing information]. Research
Triangle Park, NC: Grifols Therapeutics LLC; January 2022.
12. Liesner RJ. Prophylaxis in Haemophilic Children. Blood Coagul Fibrinolysis.
1997;8(suppl 1):S7-S10. [PubMed 9351529]
13. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child.
Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
14. Lusher JM. Transfusion Therapy in Congenital Coagulopathies. Hematol Oncol Clin
North Am. 1994;8(6):1167-1180. [PubMed 7860443]
15. Manucci PM. Impact of Recombinant Factor VIII on Hemophilia Care. Vox Sang.
1994;67(suppl 3):49-52. [PubMed 7975511]
16. Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose
continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol.
1992;82(4):729-734. doi:10.1111/j.1365-2141.1992.tb06951.x [PubMed 1482660]
17. National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council
(MASAC) guidelines for perinatal management of women with bleeding disorders
and carriers of hemophilia A and B (MASAC document 251).
https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed
June 7, 2018.
18. Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-Five Years' Experience of
Prophylactic Treatment in Severe Haemophilia A and B. J Intern Med.
1992;232(1):25-32. [PubMed 1640190]
19. Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and
Gynaecologists. Management of inherited bleeding disorders in pregnancy:
Green-top Guideline No. 71 (joint with UKHCDO). BJOG. 2017;124(8):e193–e263.
doi:10.1111/1471-0528.14592 [PubMed 28447403]
20. Peterson CW. Treating Hemophilia. Am Pharm. 1994;NS34(8):57-67.
doi:10.1016/s0160-3450(15)30341-x [PubMed 7942503]
21. Poon MC, Card R. Hemophilia management in transfusion medicine. Transfus
Apher Sci. 2012;46(3):299-307. doi:10.1016/j.transci.2012.03.020 [PubMed
22503305]
22. Prelog T, Dolničar MB, Kitanovski L. Low-dose continuous infusion of factor VIII in
patients with haemophilia A. Blood Transfus. 2016;14(5):474-480. [PubMed
26674820]
23. Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for
treatment of bleeding and surgery in haemophilia. Haemophilia. 1995;1(suppl
1):8-13. doi:10.1111/j.1365-2516.1995.tb00104.x [PubMed 27214734]
24. Scharrer I, Bray GL, Neutzling O. Incidence of Inhibitors in Haemophilia A Patients-
-A Review of Recent Studies of Recombinant and Plasma-Derived Factor VIII
Concentrates. Haemophilia. 1999;5(3):145-154. [PubMed 10444280]
25. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet.
1995;345(8980):1312-1313. [PubMed 7746084]
26. Shord SS, Lindley CM. Coagulation Products and Their Uses. Am J Health Syst
Pharm. 2000;57(15):1403-1420. [PubMed 10938981]
27. Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the
Management of Hemophilia panelists and co-authors. WFH guidelines for the
management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.
doi:10.1111/hae.14046 [PubMed 32744769]
28. White GC, Rosendaal F, Aledort LM, et al. Definitions in Hemophilia.
Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of
the Scientific and Standardization Committee of the International Society on
Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560. [PubMed
11307831]
29. Varon D, Martinowitz U. Continuous infusion therapy in haemophilia.
Haemophilia. 1998;4(4):431-435. [PubMed 9873771]
Topic 12748 Version 201.0
© 2024 UpToDate, Inc. All rights reserved.